FDA approves Merck oral PCSK9 drug
FDA approves Merck oral PCSK9 drug LIPFENDRA (enlicitide) 20 mg tablets as an adjunct to diet and exercise to lower LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Merck said on July 16, 2026, that the once-daily macrocyclic peptide is the first FDA-approved oral PCSK9 inhibitor.
Contents10 sections
Key Takeaways
- FDA approved LIPFENDRA (enlicitide) 20 mg once daily to reduce LDL-C in adults with hypercholesterolemia, including HeFH.
- CORALreef Lipids showed a 56% placebo-adjusted LDL-C cut at week 24; CORALreef HeFH showed 59%.
- Merck describes enlicitide as a novel oral macrocyclic peptide that binds PCSK9 and blocks its interaction with LDL receptors.
- Cardiovascular outcomes are still under study in CORALreef Outcomes (NCT06008756); morbidity/mortality benefit is not yet established.
LIPFENDRA at a glance
| Field | Detail |
|---|---|
| Drug | LIPFENDRA (enlicitide) tablets 20 mg |
| Company | Merck (MSD outside the U.S. and Canada) |
| Decision | U.S. FDA approval announced July 16, 2026 |
| Indication | Adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including HeFH |
| Class | First FDA-approved once-daily oral PCSK9 inhibitor (per Merck) |
| Pivotal trials | CORALreef Lipids (NCT05952856); CORALreef HeFH (NCT05952869) |
| Outcomes study | CORALreef Outcomes (NCT06008756), ongoing |
What did FDA approve?
In Merck's July 16, 2026 LIPFENDRA approval release, the company said FDA cleared enlicitide tablets 20 mg to reduce LDL-C in adults with hypercholesterolemia, including HeFH, used with diet and exercise. Merck positions the product as the first and only once-daily oral PCSK9 inhibitor approved in the United States for that use.
Enlicitide is a macrocyclic peptide designed to bind PCSK9 and inhibit PCSK9's interaction with LDL receptors, offering an oral alternative to injectable PCSK9 pathway therapies.
How much LDL-C lowering did CORALreef show?
Approval rests on two Phase 3 studies. In CORALreef Lipids, LIPFENDRA cut LDL-C by 56% versus placebo at week 24 (95% CI −61 to −51; p<0.001). From baseline, LDL-C fell 57% on drug versus a 3% rise on placebo. Secondary lipid markers also improved, including about 54% mean reduction in non-HDL-C and 50% in ApoB versus placebo increases.
In CORALreef HeFH, the placebo-adjusted LDL-C reduction was 59% at week 24 (95% CI −66 to −53; p<0.001), with a 58% reduction from baseline on drug versus a 3% increase on placebo. Non-HDL-C and ApoB fell about 52% and 48%, respectively.
What do the ClinicalTrials.gov records show?
CORALreef Lipids on ClinicalTrials.gov (NCT05952856) was a completed Phase 3, randomized, placebo-controlled study of enlicitide decanoate (MK-0616) 20 mg once daily for up to 52 weeks in adults with hypercholesterolemia needing more LDL-C lowering on stable lipid therapy. The registry lists about 2,912 participants; Merck's release cites 2,904 randomized 2:1 to drug or placebo.
CORALreef HeFH (NCT05952869) enrolled 303 adults with HeFH on moderate- or high-intensity statin therapy (with or without other lipid-modifying therapy), also randomized 2:1 to 20 mg daily or placebo for up to 52 weeks. Primary efficacy in both trials was mean percent change in LDL-C from baseline to week 24.
What is the safety profile so far?
Merck reported that adverse-reaction frequencies in CORALreef Lipids were similar between LIPFENDRA and placebo, with comparable discontinuation rates for adverse reactions. In CORALreef HeFH, the most common adverse reactions more frequent than placebo were diarrhea (7% vs 2%) and dizziness (9% vs 4%). Discontinuation rates again looked similar between arms.
Patients on other PCSK9 inhibitors were excluded from the pivotal trials without adequate washout, so head-to-head oral-versus-injectable comparisons were not the approval basis.
What remains unproven?
Merck is explicit: it is not yet known whether LIPFENDRA reduces cardiovascular morbidity or mortality. The ongoing CORALreef Outcomes trial (NCT06008756) is a Phase 3 study estimating enrollment of about 14,550 high-risk adults, with a primary endpoint of time to first CHD death–based MACE-plus events. Primary completion is estimated in late 2029.
Until outcomes data read out, the approval claim is LDL-C lowering as an adjunct to diet and exercise — not a proven reduction in heart attacks, strokes, or death.
Related NovaPharma coverage
- Chile food warning labels and obesity-risk evidence
- Why sepsis AI needs real-time data
- FDA human-factors guidance for marketing submissions
- J&J TREMFYA Phase 3 ulcerative colitis data
Frequently Asked Questions
What did FDA approve for Merck's oral PCSK9 drug?
On July 16, 2026, Merck said FDA approved LIPFENDRA (enlicitide) tablets 20 mg as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Merck called it the first FDA-approved oral PCSK9 inhibitor.
How much did enlicitide lower LDL-C in Phase 3?
In CORALreef Lipids, LIPFENDRA reduced LDL-C by 56% versus placebo at week 24. In CORALreef HeFH, the placebo-adjusted LDL-C reduction was 59% at week 24. Both trials used once-daily 20 mg oral dosing on a background of lipid-lowering therapy.
Does LIPFENDRA reduce heart attacks or strokes?
Not yet known. Merck states an outcomes trial is ongoing and that it is not yet known whether LIPFENDRA can reduce cardiovascular morbidity and mortality. That study is registered as CORALreef Outcomes (NCT06008756).
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for enlicitide.
Unlock full calendar →Merck pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
